



February 9, 2024

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Masashi Sugimoto, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL: 06-6758-8223)

Notice Concerning Revisions to the Earnings Forecast

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on November 10, 2023, as described below.

The forecast indicated below is also disclosed in the “Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024 (Nine Months Ended December 31, 2023) [Japanese GAAP].”

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2024 (April 1, 2023 to March 31, 2024)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A) (Announced on November 10, 2023)	270,000	38,500	40,000	29,000	127.12
Revised forecast (B)	272,000	40,000	41,500	30,000	131.50
Change (B-A)	2,000	1,500	1,500	1,000	
Percentage change (%)	0.7	3.9	3.8	3.4	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2023)	238,664	33,959	35,568	26,377	115.62

(2) Reasons for the revisions

The Company has revised the consolidated earnings forecast announced on November 10, 2023, as the Japan segment performed better than expected in the third quarter and its robust performance is expected to continue after the third quarter. Net sales, operating profit, ordinary profit, and profit attributable to owners of parent are all expected to exceed the previous forecast. Both sales and profit are expected to increase and reach record highs. The assumed exchange rates have been revised to 142 yen to the US dollar and 19.8 yen to the Chinese yuan.

Rohto Pharmaceutical Co., Ltd.

*The above earnings forecasts are based on information available as of the date of announcement. Final financial results may differ from the forecasts due to various factors.